{"id":"azintamide","rwe":[],"tags":[{"label":"azintamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oragalin","offLabel":[],"synonyms":["azintamide","azinthiamide","oragalin","oragallin"],"timeline":[],"brandName":"Oragalin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"azintamide","explanation":"Imagine your body's cells are like locks, and Oragalin is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't know exactly how it does that yet. This is a simplified explanation of how Oragalin might work, but more research is needed to understand its full effects.","oneSentence":"Oragalin works by binding to a specific target, although its exact target is unknown.","technicalDetail":"Oragalin's mechanism of action is not well understood, but it is believed to involve binding to a specific protein or receptor, potentially altering downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/275","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AZINTAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZINTAMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:53:56.680273","biosimilars":[],"competitors":[],"genericName":"azintamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04786795","phase":"PHASE4","title":"MITE in the Treatment of Dyspepsia After Cholecystectomy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-01","conditions":["Patients With Dyspeptic Symptoms After Cholecystectomy"],"enrollment":990,"completionDate":"2022-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004302","UNII":"ACZ6L64B41","CHEBI":"CHEBI:135068","INN_ID":"2063","RXNORM":"402580","UMLSCUI":"C0052793","ChEMBL_ID":"CHEMBL2104678","KEGG_DRUG":"D07485","DRUGBANK_ID":"DB13992","PUBCHEM_CID":"71105"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oragalin, also known as AZINTAMIDE, is a small molecule drug in the azintamide class. Its target and exact mechanism of action are unknown. It is not FDA approved for any indications. The commercial status of Oragalin is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety and efficacy.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}